Elicio Therapeutics, Inc. (ELTX)
NASDAQ: ELTX · Real-Time Price · USD
2.980
-0.060 (-1.97%)
Aug 24, 2026, 4:00 PM EDT - Market closed
Elicio Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 23.48 | 18.56 | 17.62 | 12.89 | 6.16 | 9.28 |
Cash & Short-Term Investments | 23.48 | 18.56 | 17.62 | 12.89 | 6.16 | 9.28 |
Cash Growth | 6.30% | 5.36% | 36.64% | 109.45% | -33.66% | -38.01% |
Prepaid Expenses | 1.57 | 0.56 | 1.65 | 2.43 | 2.27 | 0.18 |
Restricted Cash | - | - | 1.18 | 0.72 | 1.64 | 0.15 |
Other Current Assets | 0.44 | 0.19 | 0.24 | 0.3 | 0.65 | 0.76 |
Total Current Assets | 25.49 | 19.31 | 20.69 | 16.35 | 10.72 | 10.36 |
Property, Plant & Equipment | 4.51 | 5.08 | 6.19 | 7.28 | 8.5 | 0.89 |
Other Long-Term Assets | 1.34 | 1.47 | 1.3 | 3.52 | 3.45 | 3.57 |
Total Assets | 31.33 | 25.86 | 28.18 | 27.15 | 22.66 | 14.81 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 0.84 | 0.67 | 1.04 | 4.37 | 2.81 | 1.68 |
Accrued Expenses | 7.29 | 6.43 | 8.42 | 3.76 | 1.94 | 2.32 |
Short-Term Debt | - | - | - | - | - | 11.8 |
Current Portion of Leases | 1.07 | 1.01 | 0.9 | 0.91 | 0.69 | - |
Other Current Liabilities | - | - | 1.17 | 0.72 | 1.44 | 3.09 |
Total Current Liabilities | 9.2 | 8.11 | 11.52 | 9.76 | 6.87 | 18.88 |
Long-Term Debt | 9.54 | 9.41 | 20.03 | - | - | - |
Long-Term Leases | 3.54 | 4.09 | 5.11 | 6.01 | 6.79 | - |
Other Long-Term Liabilities | 1.12 | 2.62 | 2.83 | 0.01 | 0.09 | 0.03 |
Total Liabilities | 23.39 | 24.23 | 39.49 | 15.77 | 13.75 | 18.91 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.22 | 0.18 | 0.11 | 0.1 | 0 | 0.17 |
Additional Paid-In Capital | 261.71 | 235.41 | 183 | 153.83 | 4.86 | 4.09 |
Retained Earnings | -253.71 | -233.67 | -194.1 | -142.2 | -107.01 | -78.8 |
Treasury Stock | -0.15 | -0.15 | -0.15 | -0.15 | - | - |
Comprehensive Income & Other | -0.13 | -0.13 | -0.18 | -0.2 | - | - |
Total Common Equity | 7.94 | 1.64 | -11.31 | 11.37 | -102.15 | -74.54 |
Shareholders' Equity | 7.94 | 1.64 | -11.31 | 11.37 | 8.92 | -4.1 |
Total Liabilities & Equity | 31.33 | 25.86 | 28.18 | 27.15 | 22.66 | 14.81 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 14.15 | 14.51 | 26.04 | 6.92 | 7.48 | 11.8 |
Net Cash (Debt) | 9.33 | 4.05 | -8.42 | 5.98 | -1.33 | -2.52 |
Net Cash Growth | 29.86% | - | - | - | - | - |
Net Cash Per Share | 0.54 | 0.26 | -0.69 | 1.18 | -4.19 | -0.16 |
Filing Date Shares Outstanding | 26.28 | 18.4 | 15.94 | 10.22 | 17.7 | 17.14 |
Total Common Shares Outstanding | 21.9 | 17.8 | 11.03 | 9.6 | 17.7 | 17.14 |
Working Capital | 16.28 | 11.2 | 9.17 | 6.59 | 3.85 | -8.52 |
Book Value Per Share | 0.36 | 0.09 | -1.03 | 1.18 | -5.77 | -4.35 |
Tangible Book Value | 7.94 | 1.64 | -11.31 | 11.37 | -102.15 | -74.54 |
Tangible Book Value Per Share | 0.36 | 0.09 | -1.03 | 1.18 | -5.77 | -4.35 |
Machinery | 1.92 | 1.92 | 1.9 | 1.82 | 2.15 | - |
Leasehold Improvements | 0.13 | 0.13 | 0.13 | 0.13 | 0.12 | - |